ABIO - ARCAバイオファ―マ （ARCA biopharma Inc.）

ARCA biopharma, Inc. (NASDAQ:ABIO – Get Rating) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 226,300 shares, a drop of 7.1% from the February 28th total of 243,500 shares. Based on an average daily volume of 38,700 shares, the short-interest ratio is […]

WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […] The post ARCA biopharma Announces 2022 Financial Results and appeared first on Businessfortnight .

ARCA biopharma press release (ABIO): Q3 GAAP EPS of -$0.16.Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options

ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.

WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […] The post ARCA biopharma Announces 2022 Financial Results and appeared first on Businessfortnight .

ARCA biopharma press release (ABIO): Q3 GAAP EPS of -$0.16.Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options

ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.

WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.

ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.

WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.

Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Click here to learn more about ABIO stock.

ARCA biopharma press release (ABIO): Q1 GAAP EPS of -$0.23.Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31, 2021

WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.